AbbVie Advances Immunology Drug Rinvoq into Phase 3 Studies for Vitiligo
AbbVie, the renowned biopharmaceutical company based in North Chicago, Illinois, has announced its plans to move forward with its highly successful immunology drug Rinvoq. Following a positive outcome in a Phase 2b study focused on non-segmental vitiligo, AbbVie is now preparing to initiate Phase 3 studies. Rinvoq's effectiveness was evaluated by measuring the percentage change from baseline in a key scoring index at week 24, compared with a placebo. The results not only met the primary endpoint but also showcased even better results at week 52.
The study also reassured researchers about the drug's safety profile, as no new safety signals were identified. Currently, there are no approved systemic treatment options for vitiligo. Therefore, AbbVie's advancement of Rinvoq into Phase 3 studies brings hope for patients suffering from this chronic skin condition.
In the ever-changing pharmaceutical landscape, AbbVie looks to address the potential decline in sales of its mega-blockbuster drug Humira, which has faced increased competition due to patent expirations. With Rinvoq and the already established psoriasis drug Skyrizi, AbbVie aims to compensate for this loss in revenue. The company projects combined risk-adjusted sales of over $17.5 billion by 2025 for Rinvoq and Skyrizi. Furthermore, it anticipates that the peak sales of these two drugs will surpass $21 billion by 2027.
AbbVie's strategic move to progress Rinvoq into Phase 3 studies represents a significant milestone in combating vitiligo and meeting the unmet needs of patients. This development is a testament to the company's commitment to improving healthcare outcomes and driving innovation in the field of immunology.
All Rights Reserved © 2024
Post a comment